A synthetic lethal drug for microsatellite instability cancers
In a phase 1 trial, inhibition of the Werner syndrome helicase (WRN) enzyme exploits a new synthetic lethal vulnerability in cancers with microsatellite instability, offering a new way to target these tumors beyond immune checkpoint inhibition.